| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $339,155,131 | 45 | 100 |
| Sandler Laura Lee | Chief Operating Officer | 0 | $0 | 9 | $2.02M | $-2.02M |
| Goncalves Joana | Chief Medical Officer | 0 | $0 | 11 | $5.07M | $-5.07M |
| Agarwal Arjun | Senior Vice President, Finance | 0 | $0 | 10 | $5.08M | $-5.08M |
| Quinlan Paul T | General Counsel | 0 | $0 | 5 | $6.53M | $-6.53M |
| Dambkowski Carl | director | 0 | $0 | 3 | $8.65M | $-8.65M |
| Klein Lawrence Otto | Chief Executive Officer | 0 | $0 | 6 | $11.79M | $-11.79M |
| Fairmount Funds Management LLC | 0 | $0 | 1 | $300.01M | $-300.01M |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an …
Over the last 12 months, insiders at Oruka Therapeutics, Inc. have bought $0 and sold $339.16M worth of Oruka Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Oruka Therapeutics, Inc. have bought $1.41M and sold $339.16M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 88,794 shares for transaction amount of $1.02M was made by Venrock Healthcare Capital Partners III, L.P. (10 percent owner) on 2025‑02‑14.
| 2026-11-02 | Sale | Klein Lawrence Otto | Chief Executive Officer | 25,000 0.0398% | $95.61 | $2.39M | +4.32% | |
| 2026-10-20 | Sale | Quinlan Paul T | General Counsel | 9,000 0.0135% | $78.53 | $706,735 | +20.90% | |
| 2026-10-15 | Sale | Goncalves Joana | Chief Medical Officer | 7,000 0.0107% | $74.81 | $523,648 | +22.28% | |
| 2026-10-12 | Sale | Agarwal Arjun | Senior Vice President, Finance | 9,999 0.016% | $80.60 | $805,889 | +0.37% | |
| 2026-10-01 | Sale | Klein Lawrence Otto | Chief Executive Officer | 25,000 0.0416% | $83.62 | $2.09M | -3.68% | |
| 2026-09-15 | Sale | Klein Lawrence Otto | Chief Executive Officer | 2,452 0.0042% | $95.71 | $234,681 | -8.69% | |
| 2026-09-15 | Sale | Sandler Laura Lee | Chief Operating Officer | 906 0.0016% | $95.71 | $86,713 | -8.69% | |
| 2026-09-15 | Sale | Goncalves Joana | Chief Medical Officer | 7,947 0.0132% | $92.38 | $734,145 | -8.69% | |
| 2026-09-15 | Sale | Quinlan Paul T | General Counsel | 1,039 0.0018% | $95.71 | $99,443 | -8.69% | |
| 2026-09-15 | Sale | Agarwal Arjun | Senior Vice President, Finance | 560 0.001% | $95.71 | $53,598 | -8.69% | |
| 2026-09-11 | Sale | Agarwal Arjun | Senior Vice President, Finance | 9,459 0.015% | $92.23 | $872,413 | -8.66% | |
| 2026-09-01 | Sale | Klein Lawrence Otto | Chief Executive Officer | 75,000 0.124% | $91.83 | $6.89M | -4.78% | |
| 2026-09-01 | Sale | Sandler Laura Lee | Chief Operating Officer | 5,000 0.0083% | $91.82 | $459,101 | -4.78% | |
| 2026-08-17 | Sale | Goncalves Joana | Chief Medical Officer | 7,000 0.0111% | $111.84 | $782,882 | -18.67% | |
| 2026-08-14 | Sale | Quinlan Paul T | General Counsel | 52,000 0.0842% | $108.49 | $5.64M | -17.47% | |
| 2026-08-13 | Sale | Agarwal Arjun | Senior Vice President, Finance | 10,000 0.0164% | $106.66 | $1.07M | -15.23% | |
| 2026-07-15 | Sale | Goncalves Joana | Chief Medical Officer | 7,000 0.0184% | $86.28 | $603,938 | +6.69% | |
| 2026-07-13 | Sale | Agarwal Arjun | Senior Vice President, Finance | 9,999 0.026% | $84.63 | $846,180 | +9.14% | |
| 2026-07-01 | Sale | Fairmount Funds Management LLC | 3.55M 8.4175% | $84.43 | $300.01M | -1.44% | ||
| 2026-07-01 | Sale | Sandler Laura Lee | Chief Operating Officer | 5,000 0.0132% | $94.42 | $472,079 | -1.44% |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4148428 6.2656% | $412.98M | 5 | 0 | +31.21% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 99 | +130.26% | 10M | +22.58% |
| Decreased Positions | 25 | -32.89% | 3M | -6.64% |
| New Positions | 45 | New | 5M | New |
| Sold Out Positions | 9 | Sold Out | 146,174 | Sold Out |
| Total Postitions | 150 | +97.37% | 53M | +15.94% |